Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancer

1 May 2021

Abstract excerpt

Dear Editor, TMPRSS2:ERG (TE) fusion occurs in approximately 50% of all prostate cancer cases.1 However, details about altered signaling or the difference of gene expression regarding potential therapeutic targets between TE fusion-positive and negative group is yet to be fully investigated. In this study, we investigated the landscape of molecular signaling and curated potential therapeutic targets in TE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Prostate Cancer Treatment and Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34047472
DOI: 10.1002/ctm2.420

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancerPMID 34047472Read ↗

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.Semantic proximity Read ↗

Significance of the TMPRSS2:ERG gene fusion in prostate cancer.Semantic proximity Read ↗

Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.Semantic proximity Read ↗

Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.Semantic proximity Read ↗

Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumorsSemantic proximity Read ↗

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signalingSemantic proximity Read ↗

Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS FusionsSemantic proximity Read ↗

ETS fusion genes in prostate cancerSemantic proximity Read ↗

Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer.Semantic proximity Read ↗

TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancerSemantic proximity Read ↗

[TMPRSS2-ETS gene fusion in prostate cancer].Semantic proximity Read ↗

The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.